AIM
PDLI

Acrospire Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Acrospire Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,898
Closed -$24K – 2080
2017
Q2 		$24K Sell
9,898
-27,332
-73% -$62.9K 0.02% 1433
2017
Q1 		$85K Sell
37,230
-92,250
-71% -$204K 0.07% 442
2016
Q4 		$274K Buy
129,480
+58,858
+83% +$164K 0.11% 182
2016
Q3 		$237K Buy
70,622
+5,281
+8% +$16.8K 0.16% 83
2016
Q2 		$205K Sell
65,341
-25,800
-28% -$86K 0.15% 64
2016
Q1 		$303K Buy
+91,141
New +$284K 0.21% 27

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acrospire Investment Management's PDLI Position: Q3 2017 in Review

Acrospire Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2017, closing a stake of 9,898 shares — an estimated $24K sold.

Acrospire Investment Management first reported a position in PDLI in Q1 2016 and held it in 6 quarters. The position peaked at $303K in Q1 2016. 186 funds tracked by Wall St. Rank hold PDLI as of Q3 2017.

  • Acrospire Investment Management reported no remaining PDL BioPharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 9,898 PDL BioPharma, Inc. shares in Q3 2017, an estimated $24K.
  • Acrospire Investment Management first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's PDL BioPharma, Inc. position peaked at $303K in Q1 2016.
  • 186 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.